Journal of Communicable Diseases
Volume 58, Issue 1 - 2026, Pg. No. 60-71
Peer Reviewed & Open Access Journal

Research Article

Evaluating the Impact of Vitamin Supplementation on Recovery from Adenovirus-Associated Cough and Respiratory Symptoms

Suad Hammood Al Bashar

Department of Biology, College of Education for Women, Tikrit University, Tikrit, Iraq

DOI: https://doi.org/ 10.24321/0019.5138.202608

I N F O

E-mail Id:
Suad.hammood@tu.edu.iq
Orcid Id:
https://orcid.org/0009-0001-8806-1240

How to cite this article:
Basher S H A, Evaluating the Impact of Vitamin Supplementation on Recovery from Adenovirus-Associated Cough and Respiratory Symptoms. J Commun Dis. 2026;58(1):60-71.

Date of Submission: 2025-09-03
Date of Acceptance: 2025-10-01

A B S T R A C T

Introduction: Adenovirus-associated respiratory infection has a very important impact on worldwide health, usually presenting as prolonged cough and respiratory symptoms. This research intends to assess the efficacy of vitamin supplementation (vitamins A, C, and D, and minerals like zinc) on improvement in recovery time and severity of symptoms in patients with adenovirus-induced respiratory disease.

Methods: A double-blind randomised controlled trial (RCT) was performed on 300 patients between 18 and 65 years of age with adenovirus infection. The patients were allocated into two groups: one was given vitamin supplementation and the other a placebo. Severity of symptoms, time to recovery, viral load decrease, and inflammatory markers (C-reactive protein and interleukin-6) were monitored for 14 days. Kaplan-Meier survival analysis and t tests were employed to determine group differences.

Results: Though vitamin supplementation caused a small decrease in time to recovery, there was no statistically significant improvement in symptom intensity ($p > 0.05$). Biomarker analysis was suggestive of immune modulation effects, but overall, vitamins alone were not a sure fix for symptoms of adenovirus-associated respiratory infection.

Conclusion: This research presents empirical data from a controlled clinical trial, addressing the gap in research on vitamin supplementation in recovery from adenovirus-related respiratory illness. The observations indicate that although vitamin supplementation can complement immune function, it is not an independent therapy for adenovirus-induced respiratory manifestations. Future studies should investigate optimal levels of vitamins, any synergistic effects with antiviral medications, and efficacy in high-risk groups.

Keywords: Adenovirus, Vitamin Supplementation, Respiratory Symptoms, Immune Response, Recovery Time, Randomised Controlled Trial

Introduction

Adenoviruses are a major cause of respiratory disease globally, leading to chronic cough, congestion, and other symptoms that may persist for weeks. Due to their broad impact, researchers have investigated several interventions to reduce symptoms and accelerate recovery (Alexandrovich, 2018). Among these, vitamin supplementation has been of interest because of its possible immunomodulatory effects. The supplementation includes vitamins C and D, and minerals like zinc, which are well known for their immune-promoting effects, though their function related to viral respiratory illnesses is still being actively researched.

Prior research has shown that micronutrient supplementation can enhance immune resilience, but has left unclear the degree to which vitamins generally affect adenovirus-associated respiratory infections (Nagaria, 2023). This study seeks to determine the efficacy of vitamin supplementation in alleviating symptom severity and recovery time in adenovirus-infected subjects. By comparing clinical results in supplemented versus placebo groups, this study attempts to offer empirical proof regarding the use of vitamins in the management of respiratory health.

Overview of Adenovirus-Associated Respiratory Illnesses

Adenoviruses are a family of non-enveloped, double-stranded DNA viruses that are implicated in a broad spectrum of infections, especially of the respiratory tract (Li, 2022). The viruses are very contagious and account for a high percentage of viral respiratory diseases, especially in children, immunocompromised patients, and military recruits. Adenovirus-associated respiratory illness typically presents as pharyngitis, bronchitis, pneumonia, and croup, with fever, sore throat, cough, nasal congestion, and, in the case of severe illness, shortness of breath. In contrast to rhinovirus-induced common colds, adenovirus infection can result in extended illness and secondary complications like acute respiratory distress syndrome and secondary bacterial infections.

The virus is transmitted by respiratory droplets, direct contact, and fomites, and it is hard to contain in closed groups like schools, dormitories, and military camps. Most adenovirus infections are self-limiting, but certain serotypes like Ad3, Ad7, and Ad14 have more serious respiratory complications. Although they are common worldwide, there are no antiviral agents in general use to treat adenovirus infection, and the treatment is mainly based on symptom relief, supportive therapy, and immune system modulation (Wang, 2020). Accurate elucidation of the pathophysiology of adenoviral respiratory disease is essential to assess the likely effectiveness of potential treatments, such as vitamin supplementation, to improve the outcome and reduce symptoms.

Role of the Immune System in Recovery from Respiratory Infections

The immune response is pivotal to the defence against and recovery from adenovirus-related respiratory infections, involving a coordinated interaction of innate and adaptive immunity. With adenoviral infection, the innate immune system of the body, the first line of defence, calls into action pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), which recognise viral elements and initiate the immediate response (Olin, 2018). This causes the stimulation of interferons (IFNs), natural killer (NK) cells, and pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), that help confine the spread and viral replication. Despite these, adenoviruses have developed mechanisms for avoiding defence, resulting in delayed immune clearance and symptom presentation. This is later met by a specific response of the adaptive immunity composed of T-cells and B-cells. Cytotoxic T lymphocytes (CTLs) eliminate infected cells, while B-cells form neutralising antibodies, which inhibit subsequent infection. The effectiveness of the immune response affects the duration and severity of the disease (Raju, 2022). Immunocompromised people, e.g., elderly people, people with chronic illnesses, or recipients of immunosuppressive treatments, develop lengthy and severe infections because their defensive mechanisms are weak.

Effective immune response is contingent on several factors, such as genetics, environmental exposures, nutritional status, and general well-being. Here, vitamins and micronutrients are crucial to modulate the immune response, boost antiviral defence, and facilitate speedy recovery from infection. Opting for an efficient immune response via specific nutritional strategies, such as vitamin supplementation, could prove effective in enhancing recovery patterns in patients of adenovirus-caused respiratory diseases (Marusca, 2023).

Potential of Vitamin Supplementation in Viral Respiratory Infections

Vitamin supplementation has been widely studied for its potential role in immune function and mitigation of viral respiratory infections, including adenoviral infections (Pludowski, 2023). A number of vitamins, such as vitamins A, C, D, and E, have been shown to boost the immune response, reduce inflammation, enhance antiviral resistance, and enable repair of tissue in the respiratory tract. Vitamin

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

A plays an essential role in the preservation of mucosal barriers and the improvement of the functions of T and B lymphocytes, which are important for viral infection (Chung, 2020). Vitamin C, as an antioxidant, reduces oxidative stress, regulates cytokines, and augments immune cell function, including neutrophils and macrophages. Experiments revealed that large amounts of vitamin C are capable of reducing the severity of respiratory infections' inflammation and shortening their duration, by increasing immune cell activity and decreasing inflammation-mediated damage in the lungs. Vitamin D, also known as the "sunshine vitamin," was found to mediate innate and adaptive immunity. It increases the generation of antimicrobial peptides like cathelicidins and defensins that neutralise viral pathogens and control the inflammatory reaction to avoid undue tissue damage. A number of clinical trials have shown that supplementation with vitamin D lowers the incidence of respiratory infection and improves the outcome of viral illnesses in patients and hence is a promising intervention for adenovirus-caused respiratory symptoms (Martineau, 2019). Secondly, vitamin E, being another extremely effective antioxidant, sustains the functional activity of immune cells and preserves lung tissues against damage by viral infection-induced oxidising effects (Simanek, 2024).

According to Demay, while there is no official remedy for adenovirus-induced respiratory illnesses, a perfectly balanced intake of these vitamins through diet or supplements would significantly boost immune power, support recovery, and reduce the severity of symptoms (Demay, 2024). Additional clinical research is needed to establish optimal dosages and mixtures of vitamin supplementation for efficient control of adenovirus-induced respiratory complications (Kumar, 2015).

Literature Review

This literature review addresses the critical role of vitamins in immunomodulation and their potential therapeutic applications in viral respiratory infections, highlighting adenovirus symptoms. It synthesises current research on vitamin supplementation, immune response, and the relevance of such supplementation to recovery from respiratory infections.

Vitamins and Immune Modulation: A Foundation for Antiviral Defence

Zdrenghea et al. (2017) examined the role of vitamin D beyond its traditionally well-understood role in bone homeostasis, highlighting its regulatory and modulatory role in various physiological processes, including host defence, inflammation, immunity, and epithelial repair. Their study indicated that patients with respiratory illness frequently had vitamin D deficiency, suggesting that supplementation would have significant benefits. Respiratory viral infections, recognised as direct aetiologies of acute exacerbations and hospitalisation in children and adults with asthma and other airway diseases, were directly relevant to this case. Respiratory monocytes, macrophages, and epithelial cells in the study were noted to naturally express the vitamin D receptor, through which vitamin D might play a role in protecting against respiratory infections. However, even with promising *in vitro* results, their *in vivo* effects were uncertain. The review provided a comprehensive overview, however, of *in vitro* evidence for the role of vitamin D in antiviral innate immunity, the frequency of vitamin D deficiency in respiratory illnesses, and the protective effect of supplementation against respiratory viral infections in healthy individuals and chronic respiratory patients. Lastly, the researchers made recommendations to optimise the effectiveness of vitamin D as an adjuvant in preventing and treating acute respiratory infections.

Huang et al. (2018) discussed the importance of Vitamin A as a vital micronutrient for preserving vision, facilitating growth and development, and maintaining epithelial and mucus integrity within the body. It is an anti-inflammatory vitamin, which was found to be essential for strengthening immune function. The study noted its contribution to the development of the immune system and regulatory functions in both cellular immunity and humoral immune responses. In addition, vitamin A showed therapeutic activity in the treatment of infectious diseases. To better describe the relationship between nutrition and immune function, the authors summarised recent literature on the role of vitamin A in immunity and briefly described its clinical applications in the management of infectious diseases.

Adenovirus-Associated Respiratory Infections: Clinical Challenges and Treatment

Kujawski et al. (2021) investigated the epidemiology of human adenoviruses (HAdVs) in university settings, with reports of HAdV-related respiratory illness outbreaks in fall 2018 and spring 2019 at five US universities. There were 168 cases identified with a median age of 19 years, and 61% of them were male. Of these cases, 11 were hospitalised, including 10 with pneumonia, and two deaths occurred. Respiratory specimens were tested by type-specific real-time polymerase chain reaction assays, and whole genome sequencing revealed HAdV types 4 and 7, and genome types 4a1 and 7d. Symptom manifestation, absenteeism, and social history were quantified using

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

medical record review and surveys, and it was established that 80% of the respondents were absent from one or more classes due to illness. The findings had revealed that HAdV outbreaks were a cause of significant morbidity and educational disruption in otherwise healthy young adults, emphasising the significance of recognising HAdVs as potential aetiologies of respiratory infection in congregate settings like college campuses.

Koren et al. (2016) first analysed adenoviruses using single-reaction PCR, followed by a multiplex PCR assay for other respiratory viruses, enabling broader pathogen detection. The median age of adenovirus-positive cases in this study was 3.4 years, and the most common adenovirus species identified was C, especially in children. The diseases were typically mild, with cough (90%), fatigue (79%), and rhinorrhoea (74%) being the most prevalent. Infections caused by non-C adenovirus species were identified as being associated with more severe disease, suggesting potential species-specific differences in virulence or host response. In addition, half of the adenovirus-positive samples were co-infected with other respiratory viruses.

Evidence of Vitamin Supplementation in the Management of Viral Respiratory Infections

Vlieg-Boerstra et al. (2022) tested the efficacy of nutrient supplementation in averting viral respiratory tract infections (RTIs), including COVID-19, via systematic review and meta-analysis. They evaluated a range of nutrients required for immune function, e.g., several micronutrients, vitamins A, B12, C, D, and E, beta-carotene, zinc, iron, and long-chain polyunsaturated fatty acids. Following a review of 93 studies with 199,055 participants from 37 countries, the meta-analysis produced inconsistent results. Zinc supplementation revealed a substantial protective impact against RTIs in Asian children (RR: 0.86), whereas vitamin D decreased the occurrence of RTIs in North American adults (RR: 0.82). Supplementation did not have yielded no significant influence on prevention of RTIs in the general population on the prevention of RTIs in the general community. The review also found that stratified-by-nutritional-status studies revealed that zinc was more efficacious in children with low serum zinc levels.

Potential of Combined Vitamin Supplementation in Targeting Multidimensional Immune Pathways

Fekete et al. (2023) explored the increasing public health issue of cognitive impairment and dementia, especially with an ageing global population. These disorders not only impact individual well-being but also place a substantial economic burden on the healthcare system. In their detailed narrative review, they critically appraised the role of nutritional supplements in preventing cognitive decline. The review focused on the efficacy of vitamins, minerals, antioxidants, and other nutritional supplements, as reported in randomised controlled trials, observational studies, and meta-analyses. The review was drawn upon to underscore the importance of variables like dosage, bioavailability, response to the individual, safety issues, and potential interactions with conventional therapy. From this perspective, the review aimed to provide health professionals and researchers with evidence-based recommendations on nutritional supplementation for mental health.

Hornsby et al. (2018) established a linear correlation between overall survival (OS) and 25D level, with an optimal cut-off at 10 ng/mL. The median OS of 12.3 months in patients with a level of less than 10 ng/mL, when compared with the median OS of 24.5 months in those with a level of more than 10 ng/mL, established a clear relationship between the 25D level and OS. An elevated neutrophil-to-lymphocyte ratio was the strongest independent predictor of vitamin D deficiency, as identified in the Least Absolute Shrinkage and Selection Operator (LASSO) analysis. The study also observed that low vitamin D status, together with increased neutrophil-to-lymphocyte ratio (NLR), correlated with reduced survival, while increased vitamin D status and reduced NLR correlated with increased survival. In addition, vitamin D deficiency was related to inappropriate peripheral immune cell frequencies, including increased T-CD4+ and lower B lymphocyte frequencies. These findings suggest that NLR is a reliable predictor of vitamin D deficiency and that vitamin D, as well as immune dysfunction-targeted therapies, might enhance the prognosis of metastatic colorectal cancer patients.

Research Gap

Although extensive literature is available on the overall function of vitamins in immune response, specific research regarding the impact of vitamins on adenovirus-related respiratory infections has not been found. Current sources predominantly study influenza and other prevalent viral illnesses, with little emphasis on adenovirus. Even less common are randomised controlled studies that apply a framework, resulting in inconclusive results. Moreover, most studies have investigated individual vitamins, not their collective influence, which may be decisive in treating several immune pathways at once. The current study attempts to bridge these gaps by conducting a strict clinical trial to assess if vitamin supplementation is quantitatively effective on adenovirus recovery. The findings will add to

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

the current debate about employing non-pharmaceutical interventions for viral respiratory infections, providing new insights for clinical practice and public health policy.

Research Objectives

The aim of this study is to evaluate the impact of vitamin supplementation on recovery from adenovirus-associated respiratory and cough symptoms. The research evaluates the effect of vitamins on recovery time, compares symptom reduction severity between the supplementation and control groups, and analyses how vitamins like C and D, and minerals like zinc, impact immune response and recovery. Some of the major objectives and research questions are provided below:

- To evaluate the impact of vitamin supplementation on the recovery time of individuals with adenovirus-associated cough and respiratory symptoms
- To compare symptom severity reduction between the vitamin supplementation group and the placebo group over a 14-day period
- To analyse the potential role of vitamins in modulating immune response and expediting recovery
- To assess whether specific vitamins (like A, C, and D) and minerals (like zinc) contribute differently to symptom improvement
- To provide empirical evidence for healthcare professionals on the effectiveness of vitamin supplementation in managing adenovirus infections

Research Methodology

The study employed a double-blind randomised controlled trial (RCT) to determine the impact of vitamin supplementation on recovery in patients with adenovirus-associated respiratory disease and cough. The study included two groups: a group that was administered vitamin supplementation (vitamins A, C, and D, along with zinc) and another group that received a placebo. The study aimed at determining recovery time, alleviation of symptom severity, immunomodulation, and whether some vitamins influence recovery. Data were collected using patient self-report symptom diaries and laboratory testing, and were analysed using statistical methods, including Kaplan-Meier survival analysis, t tests, and multivariable regression, to ascertain the efficacy of vitamin supplements in adenovirus symptom control.

Study Design

The study employed a double-blind randomised controlled trial (RCT) design to evaluate the effect of vitamin supplementation on the recovery of patients with adenovirus-associated cough and respiratory symptoms. A placebo-controlled approach was used to allow comparison between the vitamin supplementation group and the control group, thereby ensuring valid and reliable assessment of the intervention effect.

Study area

The study was conducted at the outpatient respiratory clinic of a tertiary care teaching hospital in Baghdad, Iraq, from January 2023 to December 2023. Ethical approval for the study was obtained from the Institutional Ethics Committee of the same institution. All procedures were carried out in accordance with the Declaration of Helsinki and relevant ethical guidelines. Written informed consent was obtained from all participants prior to their inclusion in the study.

Study Population

A total of 300 adult patients aged 18–65 years with confirmed adenovirus infection were enrolled in the study. Participants were recruited from the outpatient respiratory clinic of Baghdad Teaching Hospital, Baghdad Medical City, Iraq, between January 2023 and December 2023. Eligible patients were randomly assigned in a 1:1 ratio to either the Vitamin Supplementation group (n = 150) or the Placebo group (n = 150). Inclusion criteria comprised laboratory-confirmed adenovirus infection (via polymerase chain reaction [PCR] or antigen testing), presence of respiratory symptoms within the preceding five days, and no history of vitamin supplementation in the previous month. Exclusion criteria included patients with chronic respiratory diseases, those receiving immunosuppressive therapy, pregnant or lactating women, and individuals with known vitamin allergies or intolerance.

Inclusion Criteria

- Patients aged 18–65 years diagnosed with adenovirus infection using polymerase chain reaction (PCR) or antigen test
- Presence of respiratory symptoms (cough, sore throat, congestion, and shortness of breath)
- Onset of symptoms in the past five days
- No history of vitamin supplementation for a minimum of one month prior to enrolment.

Exclusion Criteria

- Patients with chronic respiratory diseases (e.g., COPD and asthma)
- Individuals on immunosuppressive therapy
- Pregnant or lactating women
- Participants with vitamin allergies or intolerance

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

Sample Size Calculation

The study tried to determine the impact of vitamin supplementation on the recovery from adenovirus-linked cough and respiratory symptoms in 300 subjects. The subjects were randomly assigned to two groups: 150 individuals in the group receiving vitamin supplementation and 150 individuals in the placebo group. Sample size was determined through a power analysis, where an 80% power was used to detect a difference of 10% in the recovery rate of the symptoms between groups, with a significance level (α) of 0.05. This sample size ensures 80% statistical power to detect a 10% difference in recovery rates between groups at a significance level of $\alpha = 0.05$.

Intervention Groups

The research consisted of two intervention groups: the Vitamin Supplementation Group and the Placebo Group. Both groups were monitored during the treatment period in an attempt to assess the effectiveness of vitamin supplementation on the recovery from adenovirus-associated cough and respiratory illness.

- **Vitamin Supplementation Group:** The Vitamin Supplementation Group was supplemented daily with a combination of minerals and vitamins. The supplementation consisted of vitamin C (1000 mg), vitamin D3 (2000 IU), zinc (30 mg), and vitamin A (5000 IU). They were chosen because of their potential roles in immune function maintenance and recovery from respiratory infections.
- **Placebo Group:** The Placebo Group was given a pill identical in appearance to that given to the Vitamin Supplementation Group but containing no active ingredient. This was a control to enable a comparison of the effect of the actual vitamin supplementation with a placebo and to ensure that any resulting benefits were actually caused by the supplementation and were not psychological or due to any other reason.
- **Treatment duration:** Both groups received their respective interventions (vitamin supplementation or placebo) once daily for a duration of 14 consecutive days. Adherence was monitored through daily participant diaries and pill count at scheduled follow-up visits on Days 7 and 14. Any adverse events or protocol deviations were recorded throughout the treatment period.

Outcome Measures

The outcome measures played a critical role in ascertaining the efficacy of vitamin supplementation in the process of recovery from adenovirus-linked cough and respiratory symptoms. They were used to establish the primary and secondary outcomes of the study, including symptom relief, viral load reduction, and immune marker response within a certain time frame.

Primary Outcome

The key outcome measure used in the study was the symptom resolution time, which was recorded daily over a period of 14 days. The measure allowed us to determine how long the participants would take to recover from adenovirus-induced symptoms such as cough and breathing trouble after vitamin supplementation. Multiple measurements on a daily basis allowed us to get the real measure of symptom development and compare the course of recovery for different participants.

Secondary Outcomes

- **Change in Cough Severity Score:** The cough severity was recorded on a scale of 0–10, with increased severity being higher on the scale.
- **Hospitalisation Rate for Worsening Symptoms:** This measure reflected the number of participants who were hospitalised for worsening symptoms throughout the study.
- **Viral Load Reduction:** Nasopharyngeal swabs were collected on days 1, 7, and 14 to quantify viral load changes.
- **Blood Immune Response Markers:** Samples of blood were tested for markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) levels in order to evaluate immune response and inflammation.

Data Collection and Analysis

Data collection involved the gathering of baseline demographic information, such as age, gender, and pre-existing comorbidities, along with clinical information regarding the severity and duration of adenovirus-related cough and respiratory symptoms. This provided a comprehensive understanding of patient profiles and symptom patterns prior to vitamin supplementation. A representative subset of the dataset is presented in Table 1, illustrating baseline characteristics, symptom severity, recovery time, viral load, and CRP levels across selected participants.

- **Daily Symptom Logs via Patient-Reported Questionnaire:** Patients recorded daily symptom information, including the severity of cough, breathlessness, and tiredness, on a questionnaire. This helped monitor the natural history of the symptoms and the response to long-term vitamin supplementation.
- **Laboratory Tests on Days 1, 7, and 14:** Blood was tested on days 1, 7, and 14 to measure the biomarkers of immune response, inflammation, and viral load, offering objective evidence of recovery and the effects of vitamin supplementation.

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

Table 1.Representative Dataset of 14 Participants (n=300): Baseline Characteristics, Symptom Severity, Recovery Time, Viral Load (copies/mL), and CRP (mg/L) at Days 1, 7, and 14

Age (Years)	Gender	Comorbidities	Group	Severity Day 1	Severity Day 7	Severity Day 14	Recovery Time (days)	Viral Load Day 1 (copies/mL)	Viral Load Day 7 (copies/mL)	Viral Load Day 14 (copies/mL)	CRP Day 1 (mg/L)	CRP Day 7 (mg/L)	CRP Day 14 (mg/L)
56	Female	Diabetes	Vitamin Supplementation	7	6	4	6	10671	3697	-1819	10.96	6.08	3.83
46	Male	Hypertension	Placebo	9	4	3	8	10163	1872	-6152	6.01	3.63	-1.11
32	Female	Diabetes	Placebo	5	4	4	10	14795	1334	-6109	13.47	9.56	5.16
60	Male	None	Vitamin Supplementation	9	1	2	11	20634	15003	11945	10.31	6.47	1.54
25	Female	None	Placebo	5	7	0	10	14798	8893	5917	13.42	10.51	7.00
38	Female	None	Placebo	6	7	2	9	32420	25406	18829	10.80	6.62	4.63
56	Female	None	Placebo	8	2	2	14	39300	24467	21740	10.60	6.94	5.29
36	Female	None	Vitamin Supplementation	5	2	1	11	34345	21449	16922	6.05	2.34	0.60
40	Female	Diabetes	Placebo	9	6	1	14	20749	15545	10409	6.67	0.98	-0.10
28	Male	None	Placebo	6	5	1	12	48595	43014	35887	14.72	11.60	9.04
28	Male	Diabetes	Placebo	5	3	1	14	35121	24446	14978	7.28	2.08	0.31
41	Male	None	Vitamin Supplementation	7	4	4	11	47487	33455	31113	14.77	9.92	7.27
53	Female	Diabetes	Placebo	8	5	3	9	38411	28064	18466	10.32	5.48	0.74
57	Male	None	Vitamin Supplementation	5	0	0	11	43361	28450	25003	6.36	1.04	-1.68

Statistical Analysis

Descriptive Statistics

In this study, descriptive analysis was performed using IBM SPSS Statistics (Version 26.0). Continuous variables (age, symptom severity scores, viral load, CRP, and IL-6) were summarised as mean ± standard deviation (SD) for normally distributed data, and as median with interquartile range (IQR) for non-normally distributed data. Categorical variables (gender, comorbidities, treatment group) were reported as frequencies and percentages. Normality was assessed using the Shapiro-Wilk test. The summary of these descriptive statistics is presented in Table 2. The distribution of recovery time and viral load parameters across the study population is detailed in Table 3. The comparison of inflammatory biomarkers, including CRP and IL-6 levels at different time points, is

ISSN: 0019-5138
DOI: https://doi.org/ 10.24321/0019.5138.202608

summarised in Table 4.

Inferential Statistics

Inferential statistics aid in making conclusions based on sample information. Kaplan-Meier survival analysis estimates recovery time to occur, estimating probability of recovery against time, taking into account censored data. Two-sample t-tests compare two independent groups' mean symptom scores, for instance, those that received vitamin supplementation and those who did not, to ascertain whether the difference in the severity of symptoms is significant. In this study, inferential statistics were performed using SPSS v26. Kaplan-Meier survival analysis was applied to compare time-to-recovery between the two groups, with log-rank test for significance. Independent-samples t-tests were used to compare mean symptom severity scores between groups at Days 1, 7, and 14. Statistical significance was set at $p < 0.05$.

Table 2.Descriptive Statistics

Frequency (n)	Age (Years)	Severity_Day1	Severity_Day7	Severity_Day14
	300.000000	300.000000	300.000000	300.000000
Mean	40.810000	6.880000	3.423333	2.050000
Std	13.547164	1.409096	2.289453	1.412143
Min	18.000000	5.000000	0.000000	0.000000
25%	29.000000	6.000000	1.000000	1.000000
50%	41.500000	7.000000	3.000000	2.000000
75%	52.000000	8.000000	5.000000	3.000000
Max	64.000000	9.000000	7.000000	4.000000

Table 3.Recovery Time Distribution Across Vitamin Supplementation and Placebo Groups Over 14 Days

Frequency (n)	Recovery_Time	Viral_Load_Day1	Viral_Load_Day7	Viral_Load_Day14
	300.000000	300.000000	300.000000	300.000000
Mean	9.230000	30702.786667	20729.186667	14760.593333
Std	2.494898	11333.053142	11957.506957	12406.322421
Min	5.000000	10161.000000	-3597.000000	-11505.000000
25%	7.000000	20793.500000	10673.000000	3935.250000
50%	9.000000	32079.500000	21659.000000	15330.000000
75%	11.000000	39353.250000	29758.500000	24259.250000
Max	14.000000	49933.000000	44164.000000	40466.000000

Table 4.Comparison of Inflammatory Biomarker Levels (CRP and IL-6) Between Vitamin Supplementation and Placebo Groups at Days 1, 7, and 14

Frequency (n)	CRP_Day1	CRP_Day7	CRP_Day14
	300.000000	300.000000	300.000000
Mean	10.100200	5.514067	2.439633
Std	2.963818	3.248390	3.550082
Min	5.020000	-1.480000	-5.710000
25%	7.415000	2.965000	-0.205000
50%	10.320000	5.440000	2.120000
75%	12.622500	7.912500	5.502500
Max	15.000000	12.650000	10.850000

Data Preprocessing

In data preprocessing, the first process is to check for missing data. This is to confirm whether there is any significant missing data, since it may cause bias in the

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

results and affect the validity of the analysis. After detecting missing data, appropriate techniques like imputation or deletion can be applied. Following this, data normalisation and encoding categorical variables are required to bring numerical values within a consistent range in an effort to improve model performance.

- **Statistical Analysis:** Statistical comparison of symptom severity between the Vitamin Supplementation and Placebo groups is done to determine whether vitamin supplementation impacts symptom severity significantly or not. This can be done using statistical tests like the t test or ANOVA, depending on the nature of the data. Kaplan-Meier survival analysis is also performed to compare recovery time in the two groups. This method anticipates recovery over time and produces a graphical outcome of survival curves per group. T tests and ANOVA are then used to make additional comparisons between groups and provide a determination of whether or not there are statistically significant differences between the Placebo and Vitamin Supplementation groups for varying outcomes, such as recovery rate or symptom reduction.
- **Machine Learning Model**: For predictive modelling, one can utilise the machine learning algorithms like Logistic Regression or Random Forest to predict faster recovery based on vitamin supplements. The problem is to design a model that takes patient features, symptoms, and treatment groups as input features and provides the chance of faster recovery. Logistic regression may be applied for binary outcomes (e.g., recovery or not), while Random Forest may be applied to handle more complex relationships and provide more accurate predictions. These models can also further identify which variables contribute most to recovery, with implications that can be used in the decision-making of future treatments. In this study, missing data were assessed using Little's MCAR test. Cases with <5% missing values were imputed using mean substitution; those with >5% missing data were excluded. Continuous variables were normalised using min-max scaling prior to regression modelling. Categorical variables (gender, group) were encoded as binary dummy variables.

Results and Discussion

This study attempted to assess the effectiveness of vitamin supplementation in recuperation from adenovirus-cough and respiratory symptoms. A comparative assessment was done between the Vitamin Supplementation and Placebo groups to determine the trends of difference in recovery. Statistical analysis was used for assessing major parameters of symptom duration, severity decrease, and recuperation improvement rate. The findings were enlightening in terms of whether the vitamin supplement accelerated or eased recovery relative to the placebo, with potential implications for nutritional therapy in the management of adenovirus-induced respiratory illness.

Symptom Severity Analysis

The symptom severity analysis revealed that both groups experienced a reduction in symptom severity throughout the 14-day treatment, but this between-group difference was not statistically significant ($p > 0.05$). This would suggest that while vitamin supplementation did have a symptom-reducing effect, its impact was not significantly greater than the placebo. A range of possible causes for these findings exists, for example, immunity variation in immune function in participating individuals, basal medical conditions, and the potential effect of other interventions or lifestyle factors. Further, metabolism and participants' variability of nutrient intake could have contributed towards how extreme supplementation reduced the severity of the symptoms. These findings point to the complex process of symptom management and that while vitamin supplementation may be beneficial, it may not be a predictor of alleviation of symptoms over a placebo. The symptom severity analysis (as shown in Table 5 revealed that both groups experienced a reduction in symptom severity throughout the 14-day treatment, but this between-group difference was not statistically significant ($p > 0.05$). The comparative symptom

Table 5.Symptom severity and recovery parameters for both groups: recovery time (days), viral load (copies/mL), and CRP (mg/L), with the group column retained for direct inter-group comparison

Recovery _Time	Viral_Load_Day1	Viral_Load_Day7	Viral_Load_Day14	CRP_ Day1	CRP_ Day7	CRP_ Day14
6	10671	3697	-1819	10.96	6.08	3.83
8	10163	1872	-6152	6.01	3.63	-1.11
10	14795	1334	-6109	13.47	9.56	5.16
11	20634	15003	11945	10.31	6.47	1.54
10	14798	8893	5917	13.42	10.51	7.00
9	32420	25406	18829	10.80	6.62	4.63
14	39300	24467	21740	10.60	6.94	5.29

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

11	34345	21449	16922	6.05	2.34	0.60
14	20749	15545	10409	6.67	0.98	-0.10
12	48595	43014	35887	14.72	11.60	9.04
14	35121	24446	14978	7.28	2.08	0.31
11	47487	33455	31113	14.77	9.92	7.27
9	38411	28064	18466	10.32	5.48	0.74
11	43361	28450	25003	6.36	1.04	-1.68
6	31223	23580	19201	5.99	1.25	-3.26



Figure 1. Symptom Severity on Day 14 for Both Groups

severity on Day 14 between the two groups is illustrated in Figure 1.

Recovery Time Analysis

The assessment of recovery time showed that the participants who were given vitamins demonstrated a slightly higher percentage of improvement compared to the placebo group. This was also quantified as faster mean recovery time reported for the vitamin group, which may indicate that vitamins may play a role in accelerating the process of recovery. Nevertheless, the lack of a significant statistical difference here implied that while vitamins may contribute to recovery, there may be other variables that have a greater influence. Variables such as an individual's baseline health status, overall nutritional status, and genetic profile could potentially be more influential in determining the course of recovery from adenovirus-induced respiratory infections. The assessment of recovery time (as illustrated in Figure 2) showed that the participants who were given vitamins demonstrated a slightly higher percentage of improvement compared to the placebo group.

The recovery time analysis confirms a pattern of heterogeneity, whereby some in the vitamin group had a faster recovery, and others showed a pattern close to that of the placebo group. This heterogeneity suggests the complexity of recovery mechanisms, pointing to factors beyond vitamin supplementation being extremely powerful. Both the extrinsic factors, i.e., lifestyle and environmental factors, and the intrinsic factors, i.e., genetic constitution and overall health status, may be responsible for these variations. This renders it all the more necessary to look at



Figure 2. Recovery Time Distribution

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

things in a holistic perspective while evaluating the efficacy of vitamin supplements in recovery processes.

Recommendations

- **Clinical Practice:** Vitamin supplementation cannot be a first-line treatment for adenovirus-related respiratory symptoms, but could be incorporated as part of comprehensive supportive care. Evidence-based practice should be given priority by healthcare providers through symptomatic relief and antiviral investigation.
- **Future Research:** Additional research must investigate the synergy of vitamin supplementation with antiviral drugs or immune-modulating treatments to evaluate potential combined efficacy. Research should also determine whether certain subgroups (e.g., vitamin-deficient patients) have a larger therapeutic effect.
- **Public Health Considerations:** While vitamins play a critical part in overall immune well-being, public health strategies should not overly promote them in the management of acute respiratory infection. Rather, awareness programmes need to highlight the importance of an equilibrated diet, vaccination, and other scientifically proven measures of prevention.
- **Methodological Advancements:** Subsequent clinical trials must take into account larger numbers of cases, longer follow-up time, and more immune response markers to better understand the potential function of vitamins in recovery from viral infection.

Conclusion

The findings of this study reveal that while vitamin supplementation (vitamins A, C, and D, and minerals like zinc) does provide some immune support, it causes no significant decrease in the severity of symptoms in adenovirus-induced respiratory infections. Even while there was some slight decrease in the time taken to get better in the group given vitamin supplementation, statistical inference ($p > 0.05$) showed that the impacts were not high enough to provide a sole therapeutic intervention. In addition, biomarker analysis showed minimal immune-modulating activity, but no clinical effect was observed on inflammatory markers (CRP and IL-6). These results suggest that vitamins have a role in overall immune function but are insufficient to control symptoms of adenovirus-induced respiratory illness. Based on these findings, vitamin supplementation cannot be a substitute for existing medical therapy in viral respiratory infections. Future studies must aim to study optimal dosages of vitamins, interactions with antiviral treatment, and impacts in high-risk groups like immunocompromised patients or patients with chronic respiratory diseases. There is also a need for large-scale randomised controlled trials with long-term follow-up to confirm these findings and to study the long-term impact of vitamin supplementation on immune resistance and viral clearance.

Authors' Contribution:

Authors' Contribution: [Author 1]: Conceptualisation, methodology, writing – original draft. [Author 2]: Data collection, formal analysis. [Author 3]: Writing – review and editing, supervision. All authors approved the final version of the manuscript.

Declaration of Generative AI and AI-Assisted Technologies in the Writing Process:

AI-assisted tools were used for grammar and language editing only; all scientific content was generated and verified by the authors.

Source of Funding: None

Conflict of Interest: None

References

1. Alexandrovich MN, Ivanovich LN, Veniaminovich MO. Evaluation of the efficacy and safety of complex therapy of acute respiratory diseases of adenoviral etiology in young people. World J Pharm Res. 2018;7(16):1724-33. [Google Scholar]
2. Chung C, Silwal P, Kim I, Modlin RL, Jo EK. Vitamin D-cathelicidin axis: at the crossroads between protective immunity and pathological inflammation during infection. Immune Netw. 2020;20(2):e12. [PubMed] [Google Scholar]
3. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, Murad MH, Powers S, Rao SD, Scragg R, Tayek JA, Valent AM, Walsh JM, McCartney CR. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907-47. [PubMed] [Google Scholar]
4. Fekete M, Lehoczki A, Tarantini S, Fazekas-Pongor V, Csípő T, Csizmadia Z, Varga JT. Improving cognitive function with nutritional supplements in aging: a comprehensive narrative review of clinical studies investigating the effects of vitamins, minerals, antioxidants, and other dietary supplements. Nutrients. 2023;15(24):5116. [PubMed] [Google Scholar]
5. Hornsby E, Pfeffer PE, Laranjo N, Cruikshank W, Tuzova M, Litonjua AA, Weiss ST, Carey VJ, O'Connor G, Hawrylowicz C. Vitamin D supplementation during pregnancy: effect on the neonatal immune system in a randomized controlled trial. J Allergy Clin Immunol. 2018;141(1):269-78. [PubMed] [Google Scholar]
6. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. J Clin Med. 2018;7(9):258.

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608

[PubMed] [Google Scholar]
7. Koren MA, Arnold JC, Fairchok MP, Lalani T, Danaher PJ, Schofield CM, Rajnik M, Hansen EA, Mor D, Chen WJ, Ridore M, Burgess TH, Millar EV. Type-specific clinical characteristics of adenovirus-associated influenza-like illness at five US military medical centers, 2009–2014. Influenza Other Respir Viruses. 2016;10(5):414-20. [PubMed] [Google Scholar]
8. Kujawski SA, Lu X, Schneider E, Blythe D, Boktor S, Farrehi J, Haupt T, McBride D, Stephens E, Sakthivel SK, Bachaus B, Waller K, Bauman L, Marconi A, Lewis R, Dettinger L, Ernst R, Kinsey W, Lindstrom S, Gerber SI, Watson JT, Biggs HM. Outbreaks of adenovirus-associated respiratory illness on 5 college campuses in the United States, 2018–2019. Clin Infect Dis. 2021;72(11):1992-9. [PubMed] [Google Scholar]
9. Kumar SG, Majumdar A, Kumar V, Naik BN, Selvaraj K, Balajee K. Prevalence of acute respiratory infection among under-five children in urban and rural areas of Puducherry, India. J Nat Sci Biol Med. 2015;6(1):3-6. [PubMed] [Google Scholar]
10. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EA, Campbell H, Pariente AB, Bardach D, Bassat Q, Casalegno JS, Chakhunashvili G, Crawford N, Danilenko D, Do LA, Echavarria M, Gentile A, Gordon A, Heikkinen T, Huang QS, Jullien S, Krishnan A, Lopez EL, Markić J, Mira-Iglesias A, Moore HC, Moyes J, Mwananyanda L, Nokes DJ, Noordeen F, Obodai E, Palani N, Romero C, Salimi V, Satav A, Seo E, Shchomak Z, Singleton R, Stolyarov K, Stoszek SK, von Gottberg A, Wurzel D, Yoshida LM, Yung CF, Zar HJ; Respiratory Virus Global Epidemiology Network; Nair H; RESCEU Investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64. [PubMed] [Google Scholar]
11. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Janssens W, Jensen ME, Kerley CP, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S, Stelmach I, Kumar GT, Urashima M, Camargo CA, Griffiths CJ, Hooper RL. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol Assess. 2019;23(2):1-44. [PubMed] [Google Scholar]
12. Marusca LM, Reddy G, Blaj M, Prathipati R, Rosca O, Bratosin F, Bogdan I, Horhat RM, Tapos GF, Marti DT, Susan M, Pingilati RA, Horhat FG, Adelina M. The effects of vitamin D supplementation on respiratory infections in children under 6 years old: a systematic review. Diseases. 2023;11(3):104. [PubMed] [Google Scholar]
13. Nagaria TD, Shinde RK, Shukla S, Acharya S, Acharya N, Jogdand SD. The sunlight-vitamin D connection: implications for patient outcomes in the surgical intensive care unit. Cureus. 2023;15(10):e46819. [PubMed] [Google Scholar]
14. Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, Gustafsson A, Bernhardsson AK, Zhang C, Bohlin K, Brodin P. Stereotypic immune system development in newborn children. Cell. 2018;174(5):1277-92.e14. [PubMed] [Google Scholar]
15. Pludowski P. Supplementing vitamin D in different patient groups to reduce deficiency. Nutrients. 2023;15(17):3725. [PubMed] [Google Scholar]
16. Raju A, Luthra G, Shahbaz M, Almatooq H, Foucambert P, Esbrand FD, Zafar S, Panthangi V, Kurupp AR, Khan S. Role of vitamin D deficiency in increased susceptibility to respiratory infections among children: a systematic review. Cureus. 2022;14(9):e29205. [PubMed] [Google Scholar]
17. Simanek V, Dedeckova E, Topolcan O, Kralova M, Kucera R. A case study of vitamin D supplementation therapy and acute respiratory tract infection. In Vivo. 2024;38(2):949-53. [PubMed] [Google Scholar]
18. Vlieg-Boerstra B, de Jong N, Meyer R, Agostoni C, de Cosmi V, Grimshaw K, Milani GP, Muraro A, Elberink HO, Pali-Scholl I, Roduit C, Sasaki M, Skypala I, Sokolowska M, van Splunter M, Untersmayr E, Venter C, O'Mahony L, Nwaru BI. Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: a systematic review and meta-analysis. Allergy. 2022;77(5):1373-88. [PubMed] [Google Scholar]
19. Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, Omer SB, Abbas Q, Ali A, Amu A, Azziz-Baumgartner E, Bassat Q, Brooks WA, Chaves SS, Chung A, Cohen C, Echavarria M, Fasce RA, Gentile A, Gordon A, Groome M, Heikkinen T, Hirve S, Jara JH, Katz MA, Khuri-Bulos N, Krishnan A, de Leon O, Lucero MG, McCracken JP, Mira-Iglesias A, Moïsi JC, Munywoki PK, Ourohiré M, Polack FP, Rahi M, Rasmussen ZA, Rath BA, Saha SK, Simões EA, Sotomayor V, Thamthitiwat S, Treurnicht FK, Wamukoya M, Yoshida LM, Zar HJ, Campbell H, Nair H; Respiratory Virus Global Epidemiology Network. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2020;8(4):e497-510. [PubMed] [Google Scholar]
20. Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D Modulation Of Innate Immune Responses To Respiratory Viral Infections. Rev Med Virol. 2017;27(1):e1909. [PubMed] [Google Scholar]

ISSN: 0019-5138
DOI: https://doi.org/10.24321/0019.5138.202608